SCHEMBL4124557

SCHEMBL4124557

O=C(O)c1c(CO)nn2c(-c3ccc(Cl)cc3)c(-c3ccccc3Cl)cnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.41
NPC1 O15118 5/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 4/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
RXFP1 Q9HBX9 2/20 0.39
AHR P35869 1/20 0.39
EGLN1 Q9GZT9 1/20 0.37
MAP4K4 O95819 1/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2C8 P10632 1/20 0.36
CYP2C9 P11712 1/20 0.36
DHODH Q02127 1/20 0.36
TP53 P04637 1/20 0.36
SCN9A Q15858 1/20 0.35
MARS1 P56192 1/20 0.35
BRS3 P32247 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4124245 0.90 NPC1 (0.43) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL2087342 0.89 GPR119 (0.41) GPR119
SCHEMBL4108763 0.87 SMN1; SMN2 (0.47) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL4124278 0.87 MAP4K4 (0.46) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL4107563 0.86 TP53 (0.40) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL2085454 0.86 RXFP1 (0.38) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL2084318 0.83 NPC1 (0.36) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL2084056 0.83 RAB9A (0.38) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL2085649 0.83 NR3C1 (0.39) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL2084105 0.82 PTGS2 (0.38) RAB9ANPC1KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD RAB9A 364/4885NPC1 3153/4885KMT2A 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.